William Blair analyst Myles Minter downgraded Alector (ALEC) to Market Perform from Outperform without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm needs to see clinical data for Alector’s platform to evaluate its other programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector downgraded to Neutral from Overweight at Cantor Fitzgerald
- Alector downgraded to Neutral from Outperform at Mizuho
- Alector downgraded to Hold from Buy at TD Cowen
- Closing Bell Movers: Intuitive Surgical, Capital One jump after earnings
- Alector discontinues extension portion of INFRONT-3 trial